




RealRate

## PHARMACEUTICAL 2020

ENDONOVO THERAPEUTICS INC.  
Rank 322 of 362



RealRate

• Financial Strength Rankings using Artificial Intelligence

• [www.realrate.ai](http://www.realrate.ai)



## PHARMACEUTICAL 2020

### ENDONOVO THERAPEUTICS INC. Rank 322 of 362

The relative strengths and weaknesses of ENDONOVO THERAPEUTICS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ENDONOVO THERAPEUTICS INC. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 1,040% points. The greatest weakness of ENDONOVO THERAPEUTICS INC. is the variable Other Net Income, reducing the Economic Capital Ratio by 403% points.

The company's Economic Capital Ratio, given in the ranking table, is -686%, being 384% points below the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	63
Cost of Goods Sold	93
Intangible Assets	3,206
Liabilities, Current	23,623
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	4,026
Other Liabilities	155
Other Net Income	-13,505
Property and Equipment	5.9
Research and Development	0
Revenues	310
Selling, General and Administrative Expense	0

Output Variable	Value in 1000 USD
Assets	3,275
Liabilities	23,778
Expenses	4,119
Stockholders Equity	-20,504
Net Income	-17,315
Comprehensive Net Income	-17,315
Economic Capital Ratio	-686%

